UPDATE: Maxim Group Assumes Cardiff Oncology (CRDF) at Buy

August 9, 2021 8:44 AM EDT
Get Alerts CRDF Hot Sheet
Price: $6.06 -1.94%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 18 | New: 32
Trade Now! 
Join SI Premium – FREE
(Updated - August 9, 2021 8:45 AM EDT)

Maxim Group analyst Naureen Quibria assumes coverage on Cardiff Oncology (NASDAQ: CRDF) with a Buy rating and a price target of $20.00.

The analyst comments "Onvansertib is a pipeline drug that offers long-term growth opportunities. Cardiff’s PLK inhibitor, onvansertib, has ongoing studies in several metastatic cancers in combination with standard of care: in colorectal cancer patients with KRAS mutations (mCRC), in castration-resistant prostate cancer (mCRPC), and another recently initiated in pancreatic ductal adenocarcinoma (mPDAC)."

For an analyst ratings summary and ratings history on Cardiff Oncology click here. For more ratings news on Cardiff Oncology click here.

Shares of Cardiff Oncology closed at $5.76 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

Maxim Group